Fox Chase Cancer Center
foxchase.orgTotal trials
211
Active
45
Phase 3
5
Total enrollment
25,369
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 45 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | 7 | ||
| Nivolumab | — | — | — | — | 5 | ||
| Gemcitabine | — | — | — | — | 5 | ||
| carboplatin | — | — | 17 | ||||
| Enfortumab vedotin | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | — | 2 | |
| paclitaxel | — | — | 20 | ||||
| cisplatin | — | — | — | — | 9 | ||
| everolimus | — | — | — | — | 5 | ||
| docetaxel | — | — | — | — | — | 3 | |
| rituximab | — | — | — | — | — | 3 | |
| trastuzumab | — | — | — | — | 2 | ||
| Ribociclib | — | — | — | — | 2 | ||
| pemetrexed | — | — | — | — | — | 2 | |
| Etoposide | — | — | — | — | — | 2 | |
| FOLFIRINOX | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| Axitinib | — | — | — | — | — | 1 | |
| AMVAC + Nivolumab | — | — | — | — | — | 1 | |
| Bendamustine | — | — | — | — | — | 1 | |
| Arm A | — | — | — | — | — | 1 | |
| Arm B | — | — | — | — | — | 1 | |
| Guadecitabine | — | — | — | — | — | 1 | |
| FOLFOX regimen | — | — | — | — | — | 1 | |
| Ramucirumab | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Topotecan | — | — | — | — | — | 1 | |
| Lurbinectedin | — | — | — | — | — | 1 | |
| Venofer | — | — | — | — | — | 1 | |
| Talazoparib | — | — | — | — | — | 1 | |
| pacritinib | — | — | — | — | — | 1 | |
| Neratinib Pill | — | — | — | — | — | 1 | |
| Fam-Trastuzumab Deruxtecan-Nxki | — | — | — | — | — | 1 | |
| Gamitrinib | — | — | — | — | — | 1 | |
| intradermal injection of CADI-05 | — | — | — | — | — | 1 | |
| Cannabidiol | — | — | — | — | — | 1 | |
| oxaliplatin-based chemotherapy | — | — | — | — | — | 1 | |
| CBL0137 | — | — | — | — | — | 1 |
5 more active programs hidden
Next readouts
- 2020-07-12
- 2024-04-23
- 2025-12-18
- 2026-05
- 2026-05
- 2026-06
- 2026-06-30
- 2026-09-01
- 2026-09-23
- 2026-10-15
Top conditions
- Lung Cancer15
- Breast Cancer14
- Prostate Cancer12
- Colorectal Cancer12
- Unspecified Adult Solid Tumor, Protocol Specific10
- Lymphoma8
- Urothelial Carcinoma6
- Pancreatic Cancer6
Frequently asked questions about Fox Chase Cancer Center
- How many clinical trials does Fox Chase Cancer Center have on ClinicalTrials.gov?
- Fox Chase Cancer Center is listed as the lead sponsor on 211 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fox Chase Cancer Center's trials are in Phase 3?
- 5 of Fox Chase Cancer Center's trials are in Phase 3, spread across 45 active drug programs.
- What therapeutic areas does Fox Chase Cancer Center focus on?
- Fox Chase Cancer Center's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific.
- When are Fox Chase Cancer Center's next clinical trial readouts?
- Fox Chase Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma”, expected around 2020-07-12.